Prevail Therapeutics (NASDAQ:PRVL) Cut to Sell at Zacks Investment Research

Zacks Investment Research cut shares of Prevail Therapeutics (NASDAQ:PRVL) from a buy rating to a sell rating in a research note published on Saturday morning, Zacks.com reports.

According to Zacks, “Prevail Therapeutics Inc. is a gene therapy company. It focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company’s product candidate consists of PR001, PR006 and PR004 which are in clinical stage. Prevail Therapeutics Inc. is based in New York. “

Several other equities research analysts have also recently weighed in on PRVL. Wedbush restated a buy rating and set a $20.00 target price on shares of Prevail Therapeutics in a research note on Friday, November 1st. Cowen restated a buy rating on shares of Prevail Therapeutics in a research note on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Prevail Therapeutics presently has a consensus rating of Buy and a consensus price target of $16.50.

Shares of PRVL traded up $1.43 during midday trading on Friday, hitting $12.45. The company had a trading volume of 7,950 shares, compared to its average volume of 77,364. The company has a 50-day moving average price of $10.90. The company has a debt-to-equity ratio of 0.06, a quick ratio of 17.05 and a current ratio of 17.05. Prevail Therapeutics has a 1 year low of $7.41 and a 1 year high of $16.90.

Prevail Therapeutics (NASDAQ:PRVL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.12). Analysts predict that Prevail Therapeutics will post -2.73 EPS for the current year.

Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC purchased a new stake in Prevail Therapeutics during the second quarter worth approximately $194,000. BlackRock Inc. acquired a new position in Prevail Therapeutics during the second quarter worth approximately $1,320,000. Monashee Investment Management LLC acquired a new position in Prevail Therapeutics during the second quarter worth approximately $1,188,000. Cubist Systematic Strategies LLC acquired a new position in Prevail Therapeutics during the second quarter worth approximately $230,000. Finally, Orbimed Advisors LLC acquired a new position in Prevail Therapeutics during the second quarter worth approximately $182,457,000. Hedge funds and other institutional investors own 79.28% of the company’s stock.

About Prevail Therapeutics

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

See Also: Bond

Get a free copy of the Zacks research report on Prevail Therapeutics (PRVL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.